2024-10-16 - Analysis Report
## Regeneron Pharmaceuticals Inc. (REGN) Stock Analysis Report

**1. Performance Comparison:**

Regeneron Pharmaceuticals Inc. (REGN) is a biotechnology company that focuses on developing and commercializing innovative medicines for serious diseases.  

* **Cumulative Return:** 93.48%
* **S&P 500 (VOO) Cumulative Return:** 135.82%
* **Divergence:** -42.34%
* **Relative Divergence:** 33.67%

**REGN has underperformed the S&P 500 by 42.34%, ranking at the 33.67 percentile of its historical performance range relative to the index.**

**2. Recent Price Fluctuation:**

* **Closing Price:** $1015.67
* **5-Day Moving Average:** $1005.86
* **20-Day Moving Average:** $1059.31
* **60-Day Moving Average:** $1108.75

**REGN's current price is below its 5, 20, and 60-day moving averages, suggesting a downtrend in the short to medium term.**

**3. Technical Indicators:**

* **RSI:** 31.62 (Below 30, indicating oversold conditions)
* **PPO:** -0.34 (Negative, indicating downward momentum)
* **Delta_Previous_Relative_Divergence:** -25.78 (Negative, indicating short-term downward trend)
* **Expected Return:** 0.0% (Based on historical data, there is no expected return for the next 5 years compared to S&P 500).

**The technical indicators suggest that REGN is currently in an oversold and downward trend, with limited expected returns.**

**4. Recent Earnings and Outlook:**

| Date      | EPS      | Revenue        |
|-----------|----------|----------------|
| 2024-08-01| 13.25    | $3.55 Billion  |
| 2024-05-02| 6.7      | $3.15 Billion  |
| 2023-11-02| 9.48     | $3.36 Billion  |
| 2023-08-03| 9.05     | $3.16 Billion  |
| 2024-08-01| 9.05     | $3.16 Billion  |

**The latest earnings report for the quarter ending August 01, 2024, showed EPS of $13.25, exceeding analysts' expectations.  Revenue also exceeded estimates at $3.55 Billion.** 

**5. News and Recent Issues:**

* **Market Outlook:** The market outlook for REGN is currently mixed. While the recent earnings report was positive, analysts are still concerned about the company's dependence on its flagship drug, Eylea. 
* **Analyst Opinions:** Analysts are divided on REGN's future prospects. Some believe the company has a strong pipeline of potential drugs, while others are concerned about competition in the market.
* **Performance Highlights:**  REGN has experienced significant growth in recent years, but has faced challenges from increased competition. The company is also facing increasing pressure to diversify its product portfolio. 

**6. Summary:**

REGN is a biotechnology company that has shown significant growth in recent years, but its performance has been lagging the market. The company is currently facing headwinds from increased competition and is relying heavily on its flagship drug, Eylea. The recent earnings report was positive, exceeding analysts' expectations, but the market outlook is still mixed. Technical indicators suggest a short-term downtrend, with limited expected returns. Investors should carefully evaluate the company's future prospects and consider the risks associated with its dependence on Eylea.

**7.  Recommendation:**

Given the current market outlook, technical indicators, and potential risks associated with REGN's dependence on Eylea, a cautious approach to investing is recommended.  

**Disclaimer:**  This analysis is for informational purposes only and should not be considered financial advice. Always consult with a qualified financial advisor before making any investment decisions. 
